THERAVANCE BIOPHARMA, INC. Environmental Analytics
Environmental and financial analysis dashboard for THERAVANCE BIOPHARMA, INC.. Industry: MANUFACTURING
Company Overview for THERAVANCE BIOPHARMA, INC.
Highlights
Showing data for FY2022
Operational Environmental Cost
$0.66m
Operational Environmental Cost Intensity
1.28%
Total Environmental Cost
N/A
Total Environmental Cost Intensity
N/A
ΔOperational Environmental Cost (2020-2022)
$0.11m
Decoupling Rate (2020-2022)
-29%
Adjusted EBITDA
$-80m
Adjusted EBITDA Margin
-156%
Environmental cost statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| OPERATIONAL SOCIAL COST OF CARBON | ||||
| -1.14% | 8.89% | N/A | ||
| 0.28% | 0.36% | 0.42% | N/A | |
| 13.99% | 10.33% | N/A | ||
| 0.49% | 0.73% | 0.87% | N/A | |
| $1m | $1m | $1m | N/A | |
| 8.52% | 9.86% | N/A | ||
| 0.77% | 1.09% | 1.28% | N/A | |
| INDIRECT SOCIAL COST OF CARBON | ||||
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. Scope 2: Social Cost of Carbon is calculated using market-based emissions data. | ||||
Environmental cost bridge
Showing data for FY2022
Integrated financial analysis
Highlights
Showing data for FY2022
Adjusted EBITDA Margin
-156%
Adjusted EBIT Margin
-170%
EV / Adjusted EBITDA
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
EV / Adjusted EBIT
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
Integrated income statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| INCOME STATEMENT | ||||
$72m | $55m | $51m | $57m | |
| -23.03% | -7.16% | 11.82% | ||
$360m | $303m | $131m | $100m | |
| 500.55% | 548.51% | 254.68% | 174.29% | |
$-288m | $-248m | $-79m | $-43m | |
| -400.55% | -448.51% | -154.68% | -74.29% | |
$-295m | $-257m | $-86m | $-47m | |
| -410.25% | -464.06% | -168.36% | -81.71% | |
| ENVIRONMENTAL COST DATA | ||||
$1m | $1m | $1m | N/A | |
| 0.77% | 1.09% | 1.28% | 0.00% | |
| FINANCIAL DATA ADJUSTED FOR OPERATIONAL ENVIRONMENTAL COST | ||||
$-288m | $-249m | $-80m | N/A | |
| -401.32% | -449.60% | -155.96% | 0.00% | |
$-295m | $-257m | $-87m | N/A | |
| -411.02% | -465.14% | -169.64% | 0.00% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. | ||||
Environmental EBITDA bridge
Showing data for FY2022
Industry benchmark
MANUFACTURE OF PHARMACEUTICAL PREPARATIONS
Scope 1 (% of Sales)
0.42%
Scope 2 (% of Sales)
0.87%
Operational Environmental Cost Intensity
1.28%
Scope 3 (% of Sales)
N/A
Total Environmental Cost Intensity
N/A
Selected peer group
Showing data for FY2022
NAME | COUNTRY | OPERATIONAL ENV. COST | OPERATIONAL ENV. COST INTENSITY |
|---|---|---|---|
THERAVANCE BIOPHARMA, INC. | KY | $1m | 1.28% |
Loading similar companies data...
Industry distribution
Showing data for FY2022
Note: Outliers are calculated using the 1.5 * IQR method, where values outside Q1 - 1.5 * IQR and Q3 + 1.5 * IQR are considered outliers.
Estimated Social Cost of Carbon Scope 3 breakdown
Percentage breakdown of Social Cost of Carbon Scope 3 into various categories
Showing data for FY2022
SCOPE 3 CATEGORY | Company (USD) | Company % | Industry Avg (USD) | Industry Avg % |
|---|---|---|---|---|
Purchased goods (1 & 2) | N/A | N/A | N/A | N/A |
Energy-related activities (3) | N/A | N/A | N/A | N/A |
Upstream transportation (4) | N/A | N/A | N/A | N/A |
Waste (5) | N/A | N/A | N/A | N/A |
Business travel (6) | N/A | N/A | N/A | N/A |
Commuting (7) | N/A | N/A | N/A | N/A |
Upstream leased assets (8) | N/A | N/A | N/A | N/A |
Downstream transportation (9) | N/A | N/A | N/A | N/A |
Processing of products (10) | N/A | N/A | N/A | N/A |
Use of products (11) | N/A | N/A | N/A | N/A |
Final treatment of products (12) | N/A | N/A | N/A | N/A |
Downstream leased assets (13) | N/A | N/A | N/A | N/A |
Franchises (14) | N/A | N/A | N/A | N/A |
Investments (15) | N/A | N/A | N/A | N/A |
Total | $0m | 100.00% | $0m | 100.00% |
Scope 3 breakdown visualization
Showing data for FY2022